Thiotepa

Drug Profile

Thiotepa

Alternative Names: Tepadina; Thioplex

Latest Information Update: 14 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ADIENNE
  • Developer ADIENNE; Amneal Pharmaceuticals; Gruppo Italiano Trapianto di Midollo Osseo; RIEMSER Arzneimittel
  • Class Antineoplastics; Aziridines; Myeloablative agonists; Organothiophosphorus compounds
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adenocarcinoma; Cancer metastases; Graft-versus-host disease; Haematological disorders; Papilloma; Solid tumours
  • Clinical Phase Unknown Brain cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Jun 2017 Adienne completes the phase II Gandalf-01 trial in Acute lymphoblastic leukaemia and Acute myeloid leukaemia (Second-line therapy or greater) and Graft-versus-host disease (Prevention) in Italy (IV) (NCT01814488)
  • 01 May 2017 Clinical trials in Brain cancer (In children, In infants, In neonates, In adolescents, Combination therapy) in Japan (IV) (UMIN000026084)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top